Britain and America have announced a key commercial pact that will ensure zero import taxes on British pharmaceutical shipments being sold in the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise spending on medicines through the NHS. This pledge guarantees that duties on these crucial exports will be held at nothing for a period of the next three years.
This agreement is in response to previous statements to hike tariffs on branded pharmaceutical imports, with potential rates discussed up to 100%.
"This arrangement between the UK strengthens the international landscape for new treatments and introduces much-needed fairness to U.S.–U.K. pharmaceutical trade," an announcement declared.
Commercial Importance
Medicines represent one of the Britain's largest exports to the America, which is clearly the primary buyer for large British pharmaceutical firms.
Export figures reveal that in the 12 months prior to the third quarter, the UK shipped pharmaceutical products totaling billions to the US. This amount represented nearly one-fifth of total UK exports in that span.
"This guarantee safeguards work, boosts investment and facilitates the UK to establish itself as a worldwide center for medical research," a minister commented.
Key British Pledges
The agreement includes several key changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to increase overall public funding on treatments from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to stay within budget will be limited at 15%. In the past, repayments exceeded 20%.
Broader Context
The deal takes place against a long-running row between the sector and the UK government over spending levels and approval rates.
This friction were heightened by claims that American patients were paying several times more for the identical medicines than patients in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or cancelled, while major investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its overall budget over the previous ten-year period.
